Annual Report 2012 Active Biotech AB (publ)

Mon Apr 15, 2013 4:01am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

Active Biotech's Annual Report 2012 (in Swedish) is now available for download at . The English version will be available within

The Annual Report will only be digitally distributed. 

Lund, April 15, 2013

Active Biotech AB (publ)

Tomas Leanderson
President & CEO

For further information, please contact:
Hans Kolam
Tel +46 (0)46 19 20 44

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on
autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally
administered small molecule with unique immunomodulatory properties for the treatment of multiple
sclerosis, tasquinimod for prostate cancer and ANYARA primarily for the treatment of renal cell
cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. The company also
has one additional project in clinical development, the orally administered compound 57-57 for
Systemic Sclerosis. Please visit  for more

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00 
Fax: +46 46 19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make the information in
this press release public. The information was submitted for publication at 10:00 a.m. CET on
April 15, 2013.

Annual Report 2012 Active Biotech AB (publ) 


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE